Select Page

2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
“June 9, 2023 (HealthDay News) — For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors.”

ASCO 2023 roundup: Blood tests, drugs and exercise
“The American Society for Clinical Oncology’s Annual Meeting, to give it its full name, is the world’s largest cancer conference. This year, it brought more than 40,000 of oncology’s best and brightest to Chicago. From 2nd to 6th June, as they do every year, they put themselves at the centre of the planet’s health news agenda.”

Pandemic restrictions associated with a significant drop in cancer diagnoses
“Pandemic restrictions corresponded with a significant drop in diagnoses of breast, colorectal and prostate cancers as well as melanoma, according to a new Alberta study published in CMAJ (Canadian Medical Association Journal)”

Innovative Patient Education Strategies Continue to be Developed for Lung Cancer Screening
”Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patient populations who have historically experienced disparities in health care delivery, according to findings from a study presented during the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) Conference and Retreat in Philadelphia, Pennsylvania.1

Lung Cancer Screening: A Compelling Argument
“Dr. Julia Rotow, a thoracic medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, explains that EGFR-mutated lung cancer is a subset of lung cancer diagnoses that is most likely to affect younger individuals and individuals with minimal or absent history of tobacco use. This type of lung cancer occurs in approximately 15% to 20% of lung cancer cases in the United States, while in Asian countries, the rate can be as high as 50% to 60%. Therefore, it is crucial to identify this subset of lung cancer for diagnosis.”

MET status may predict benefit of amivantamab-lazertinib therapy in lung cancer subset
“CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.”

Inhalant CBD Shows Promise In Lung Cancer Battle
“Augusta University researchers have discovered inhalant cannabidiol (CBD) can effectively hinder the growth of lung cancer in mice, offering new hope in the fight against the disease.”

Quitting Smoking Early in Life Is Linked to Reduced NSCLC Mortality
“Among patients with non-small cell lung cancer (NSCLC), quitting smoking early in life was associated with lower mortality after a diagnosis of lung cancer, according to a study in JAMA Network Open.